New pill could ease rare lung disease
NCT ID NCT07441200
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an oral drug called NS-863 in 135 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goal is to see if NS-863 improves blood flow in the lungs and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NS-863 (an oral drug)
- What this could lead to
- If successful, this could point toward a new oral treatment option to help control pulmonary arterial hypertension and improve blood flow in the lungs.
- What could go wrong
- This is an early Phase 2 trial with only 135 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests